71 related articles for article (PubMed ID: 26656362)
1. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Motzer RJ; Porta C; Vogelzang NJ; Sternberg CN; Szczylik C; Zolnierek J; Kollmannsberger C; Rha SY; Bjarnason GA; Melichar B; De Giorgi U; Grünwald V; Davis ID; Lee JL; Esteban E; Urbanowitz G; Cai C; Squires M; Marker M; Shi MM; Escudier B
Lancet Oncol; 2014 Mar; 15(3):286-96. PubMed ID: 24556040
[TBL] [Abstract][Full Text] [Related]
2. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
Motzer RJ; Nosov D; Eisen T; Bondarenko I; Lesovoy V; Lipatov O; Tomczak P; Lyulko O; Alyasova A; Harza M; Kogan M; Alekseev BY; Sternberg CN; Szczylik C; Cella D; Ivanescu C; Krivoshik A; Strahs A; Esteves B; Berkenblit A; Hutson TE
J Clin Oncol; 2013 Oct; 31(30):3791-9. PubMed ID: 24019545
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib in metastatic thyroid cancer: a systematic review.
Thomas L; Lai SY; Dong W; Feng L; Dadu R; Regone RM; Cabanillas ME
Oncologist; 2014 Mar; 19(3):251-8. PubMed ID: 24563075
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
Dadu R; Waguespack SG; Sherman SI; Hu MI; Busaidy NL; Jimenez C; Habra MA; Ying AK; Bassett RL; Cabanillas ME
Oncologist; 2014 May; 19(5):477-82. PubMed ID: 24733667
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis.
Procopio G; Bellmunt J; Dutcher J; Bracarda S; Knox J; Brueckner A; Molnar I; Escudier B; Hutson TE
Br J Cancer; 2013 Feb; 108(2):311-8. PubMed ID: 23322192
[TBL] [Abstract][Full Text] [Related]
6. Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.
Janjigian YY; Vakiani E; Ku GY; Herrera JM; Tang LH; Bouvier N; Viale A; Socci ND; Capanu M; Berger M; Ilson DH
PLoS One; 2015; 10(8):e0134731. PubMed ID: 26275293
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.
Fishman MN; Tomshine J; Fulp WJ; Foreman PK
PLoS One; 2015; 10(4):e0120877. PubMed ID: 25830512
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma.
Wang HT; Xia M
Medicine (Baltimore); 2019 Jan; 98(1):e13779. PubMed ID: 30608388
[TBL] [Abstract][Full Text] [Related]
9. Cross-sectional study of therapy-related expectations/concerns of patients with metastatic renal cell carcinoma and physicians in Japan.
Kimura G; Fujii Y; Osawa T; Uchitomi Y; Honda K; Kondo M; Otani A; Wako T; Kawai D; Mitsuda Y; Sakashita N; Shinohara N
Cancer Med; 2024 Jun; 13(11):e7196. PubMed ID: 38872405
[TBL] [Abstract][Full Text] [Related]
10. Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents.
Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; Santoni M; de Cobelli O; Nolé F
Crit Rev Oncol Hematol; 2016 Mar; 99():324-31. PubMed ID: 26818051
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis.
Hu MD; Jia LH; Liu HB; Zhang KH; Guo GH
Eur Rev Med Pharmacol Sci; 2016; 20(1):64-74. PubMed ID: 26813455
[TBL] [Abstract][Full Text] [Related]
12. Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Song Y; Du C; Zhang W; Sun Y; Yang L; Cui C; Chi Y; Shou J; Zhou A; Wang J; Sun Y
Urol Oncol; 2016 Jun; 34(6):258.e15-22. PubMed ID: 26803435
[TBL] [Abstract][Full Text] [Related]
13. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.
McDermott DF; Sosman JA; Sznol M; Massard C; Gordon MS; Hamid O; Powderly JD; Infante JR; Fassò M; Wang YV; Zou W; Hegde PS; Fine GD; Powles T
J Clin Oncol; 2016 Mar; 34(8):833-42. PubMed ID: 26755520
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
Kang SK; Volodarskiy A; Ohmann EL; Balar AV; Bangalore S
Clin Oncol (R Coll Radiol); 2016 May; 28(5):334-41. PubMed ID: 26723100
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of sorafenib adjuvant therapy in northwestern Chinese patients with non-metastatic renal-cell carcinoma after nephrectomy: A multicenter retrospective study.
Wei D; Wu G; Zheng Y; Chen F; Lu J; Wang Y; He D; Wang H; Wang Z; Chen P; Wang Y; Wang Z; Ye Y; Zhu Z; Yuan J
Medicine (Baltimore); 2019 Feb; 98(5):e14237. PubMed ID: 30702581
[TBL] [Abstract][Full Text] [Related]
16.
Soldatos TG; Taglang G; Jackson DB
High Throughput; 2018 Nov; 7(4):. PubMed ID: 30477159
[TBL] [Abstract][Full Text] [Related]
17. Grade III hand-foot skin reaction induced by sorafenib.
Chiriac A; Coros MF; Podoleanu C; Stolnicu S
An Bras Dermatol; 2017; 92(4):590-591. PubMed ID: 28954127
[No Abstract] [Full Text] [Related]
18. A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients.
Huo Z; Yu S; Hong S; Cao X; Xiu L; Liao Z; Li Y; Xiao H
Onco Targets Ther; 2016; 9():3621-31. PubMed ID: 27382300
[TBL] [Abstract][Full Text] [Related]
19. The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.
Zheng Y; Wang F; Wu G; Zhang L; Wang Y; Wang Z; Chen P; Wang Q; Lu J; Wang Y; Li P; Wang J; Lu X; Yuan J
Medicine (Baltimore); 2015 Dec; 94(49):e2222. PubMed ID: 26656362
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
